经电渗法和直肠给药治疗不明病因脑膜脑炎犬的阿糖胞苷生物利用度。
The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery.
机构信息
NC State University Veterinary Hospital, 1052 William Moore Drive, Raleigh, NC, 27607, USA.
Veterinary Medical Center of Long Island, 75 Sunrise Highway, West Islip, NY, 11795-2033, USA.
出版信息
Open Vet J. 2021 Jan-Mar;11(1):36-38. doi: 10.4314/ovj.v11i1.6. Epub 2021 Jan 17.
BACKGROUND
Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous or intravenous administration.
AIM
The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery.
METHODS
Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGO™ 12.0 iontophoresis drug delivery system delivered 200 mg/m2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography.
RESULTS
The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1 μg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration.
CONCLUSION
Transdermal and rectal CA administration are not reasonable alternative routes of delivery.
背景
阿糖胞苷（CA）通过皮下或静脉给药用于治疗病因不明的脑膜脑炎（MUE）的犬。
目的
本研究旨在探索经皮离子电渗和直肠给药作为 CA 递药的替代途径。
方法
对 2 只患有 MUE 的患犬进行研究。使用 ActivaPatch® IONTOGO™ 12.0 经皮离子电渗给药系统经皮给予 200mg/m2 CA。在装置启动后通过稀疏采样技术采集血样。在另一次就诊时，经直肠给予 100mg/m2 CA。给药后通过稀疏采样技术采集血样。通过高压液相色谱法测量 CA 的血浆浓度。
结果
所有样本中经皮和直肠给予 CA 后的 CA 血浆浓度均低于定量下限（0.1μg/ml），提示经皮和直肠给予 CA 的生物利用度不足。
结论
经皮和直肠给予 CA 不是合理的递药替代途径。
Zotero 插件